Phaseline

Targets › ARG1

ARG1 (Arginase-1): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 1; Gastroenterology, Metabolic and endocrine; next expected readout Dec 2027.

Catalyzes the final step of the urea cycle by hydrolyzing L-arginine into urea, a nitrogenous waste product, and L-ornithine, a precursor to proline and polyamines; the urea cycle occurs primarily in the liver and, to a lesser extent, in the kidneys..; FUNCTION: Functions in L-arginine homeostasis in nonhepatic tissues characterized by the competition between nitric oxide synthase (NOS) and arginase for the…. (UniProt, P05089)

Open in Phaseline: the race on ARG1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tufts University8% Arginine toothpaste
Arginine-based toothpaste for xerostomia management
ARG1Phase 3XerostomiaDec 2027
Rebecca Ahrens-NicklasLNP.UCD.ABE
adenine base editor (ABE) delivered by lipid nanoparticle (LNP) for urea cycle disorder ge
CPS1, OTC, ASS1, ASL, ARG1Phase 1Urea Cycle DisordersSep 2028

Conditions

Xerostomia (1) Urea Cycle Disorders (1)

Modalities

small molecule (1), protein or peptide (1)

Companies

Tufts University (1) Rebecca Ahrens-Nicklas (1)

Related targets

CPS1 (1) OTC (1) ASS1 (1) ASL (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.